Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
the T-cell engager (TCE) space and a deepening of ties with long-term partner, Galapagos. Through this deal, the California-based big pharma company will hand over $1.68bn upfront, while pledging up to $500m in milestone payments to absorb the latter's BCMA/CD3-targeting TCE, gamgertamig (OM336). The therapy is currently in clinical development for antibody-mediated orphan diseases such as immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA). According to Citi analysts, Gilead's Ouro acquisition both aligns with the big pharma company's plans to diversify beyond HIV and complements the autoimmune push its subsidiary, Kite is currently making. While this is all standard protocol for an acquisition, Gilead may add a layer of complexity to the deal, as the company is in late-stage negotiations with Galapagos to co-develop gamgertamig. Potentially building on the pair's long-term partnership , the acquisition could see Galapagos join the equation by taking on hal
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Targets Procedure Growth With Bladder Cancer And Vision Advances [Yahoo! Finance]Yahoo! Finance
- Martin Cobb's Top Picks for March 24, 2026 [BNN Bloomberg (Canada)]BNN Bloomberg
- Golfweek Masters Survey: Favorite picture from Augusta National [USA TODAY]USA TODAY
- Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi [Seeking Alpha]Seeking Alpha
- Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website